The Latest Oncology Industry Statistics Explained
The global oncology/cancer drugs market size was valued at $97,401 million in 2017, and is expected to reach $176,509 million by 2025.
The statistic provided indicates the market size of oncology/cancer drugs in 2017 was $97,401 million and is projected to grow to $176,509 million by 2025. This represents a significant increase in market value over the specified time period, suggesting a growing demand for oncology/cancer drugs globally. Factors contributing to this growth may include advancements in cancer research and treatment technologies, an increasing prevalence of cancer worldwide, and a greater emphasis on healthcare and pharmaceutical development. The rising market size indicates a growing market opportunity for pharmaceutical companies and healthcare providers operating in the oncology sector, highlighting the importance and potential growth in this particular segment of the pharmaceutical industry.
The oncology drugs market is projected to grow at a CAGR of 7.6% between 2020 and 2025.
The statistic indicates that the oncology drugs market is expected to experience a Compound Annual Growth Rate (CAGR) of 7.6% over the period from 2020 to 2025. This projection suggests that the market for oncology drugs, which are medications used in the treatment of cancer, is anticipated to expand steadily at an average annual rate of 7.6% during this five-year timeframe. The CAGR is a useful metric for understanding the annualized growth rate of an investment or market, providing insight into the consistent rate of growth over the specified period. This forecast implies that the demand for oncology drugs is likely to increase significantly over the next five years, driven by factors such as advancements in cancer treatments, rising incidence of cancer cases, and increasing healthcare expenditures in this area.
North America dominated the market, accounting for 42% of the total revenue in 2017.
This statistic indicates that North America was the leading region in terms of market revenue in 2017. With a share of 42% of the total revenue, North America outperformed other regions in the market. This domination signifies the significant economic impact and market influence of North America compared to other regions. Companies operating in North America likely had a strong presence and market position, contributing significantly to the overall revenue generated in the market during that period. The statistic highlights the importance of North America as a key market player in driving business outcomes and shaping industry trends in 2017.
The Asia Pacific region is projected to grow at the fastest CAGR of 7.9% during the forecast period.
The statistic indicates that the Asia Pacific region is expected to experience the highest Compound Annual Growth Rate (CAGR) of 7.9% during the forecasted period. This growth rate suggests that the region’s economy, industries, or markets are anticipated to expand at a faster pace compared to other regions globally. A higher CAGR implies a more rapid rate of growth over time, signifying opportunities for businesses, investors, and other stakeholders looking to capitalize on the region’s potential growth and market expansion. This projection underscores the favorable economic conditions, market dynamics, and potential for development in the Asia Pacific region during the specified time frame.
Roche, Celgene, and Bristol-Myers Squibb are three of the world’s largest oncology drug manufacturers.
The statistic “Roche, Celgene, and Bristol-Myers Squibb are three of the world’s largest oncology drug manufacturers” indicates that these three companies are significant players in the pharmaceutical industry specifically focused on developing and manufacturing drugs for treating cancer. Their prominence in the oncology sector suggests they have a significant market share and influence in the development and distribution of cancer treatments worldwide. Given the complex and evolving nature of cancer research and treatment, the involvement of these companies highlights their expertise, capabilities, and commitment to advancing cancer therapies for the benefit of patients globally.
Targeted therapies dominated around 60% of the total oncology drugs market in 2020.
The statistic “Targeted therapies dominated around 60% of the total oncology drugs market in 2020” indicates that a significant portion of the market for drugs used in cancer treatment was comprised of targeted therapies in that year. Targeted therapies are a type of cancer treatment that focuses on specific molecular targets involved in the growth and progression of cancer cells. The fact that these therapies accounted for approximately 60% of the total oncology drug market suggests a growing trend towards precision medicine in cancer treatment, where drugs are tailored to individual characteristics of a patient’s cancer. This statistic highlights the increasing importance and utilization of targeted therapies in oncology, reflecting advancements in understanding the molecular basis of cancer and the development of more personalized treatment strategies.
The demand for personalized medicine in oncology is anticipated to grow at around 7% between 2020 and 2026.
The statistic stating that the demand for personalized medicine in oncology is expected to grow at a rate of approximately 7% between 2020 and 2026 indicates a steady and significant increase in the adoption of personalized treatment approaches within the field of oncology. This growth rate suggests a growing recognition of the benefits of tailoring medical interventions to individual patients based on their genetic makeup, lifestyle factors, and other characteristics, ultimately leading to more effective and targeted treatment strategies. The anticipated growth also implies a shift towards a more patient-centric healthcare model that prioritizes personalized care to improve outcomes and potentially reduce healthcare costs by avoiding ineffective or unnecessary treatments.
Lung cancer is the most commonly diagnosed cancer worldwide.
The statistic that lung cancer is the most commonly diagnosed cancer worldwide highlights the significant public health burden posed by this disease. Lung cancer is not only highly prevalent but also has a high mortality rate, making it a major global health concern. The statistic emphasizes the urgent need for preventive strategies, early detection methods, effective treatments, and public health initiatives to reduce the incidence and impact of lung cancer on individuals and healthcare systems worldwide. It underscores the importance of raising awareness, promoting healthy lifestyle choices, and investing in research to better understand and combat this widespread and deadly form of cancer.
Breast cancer drugs market size worldwide in 2026 will be estimated to reach 38.95 billion U.S. dollars.
The statistic indicates that the global market size for breast cancer drugs is projected to reach 38.95 billion U.S. dollars by the year 2026. This estimation reflects the expected total revenue generated from the sale of drugs specifically used for the treatment of breast cancer worldwide. The significance of this statistic lies in the growing prevalence of breast cancer cases globally, leading to an increasing demand for effective treatment options. The projected market size serves as a key indicator for pharmaceutical companies, healthcare providers, policymakers, and investors to understand the economic impact and opportunities within the breast cancer drug market in the coming years.
Oncology clinical trials accounted for approximately 28% of all type of clinical trials in 2019.
This statistic indicates that oncology clinical trials, which focus on testing new therapies and treatments for cancer patients, made up around 28% of all types of clinical trials conducted in 2019. This suggests that a significant portion of clinical research efforts during that year were dedicated to advancing the field of oncology and developing innovative approaches to treating cancer. The high percentage of oncology trials reflects the continued emphasis on improving cancer care and addressing the significant impact of cancer on global health. This data highlights the importance placed on research in oncology and the ongoing efforts to find more effective treatments and potential cures for cancer patients.
Blood cancer drug sales are projected to exceed $55.0 billion by 2024.
The statistic indicates that sales of drugs used to treat blood cancer are expected to surpass $55.0 billion by the year 2024. This projection suggests a significant growth in the market for blood cancer medications over the next few years. The increase in sales can be attributed to various factors such as advancements in treatment options, an aging population, and a rise in the prevalence of blood cancer cases. The strong demand for these drugs underscores the importance of continued research and development efforts in the field of oncology to improve outcomes for patients with blood cancer.
Prostate cancer therapeutics market is expected to grow at 5.8% CAGR from 2019 to 2026.
This statistic indicates that the market for prostate cancer therapeutics is projected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from the year 2019 to 2026. This forecast suggests that the demand for treatments and drugs for prostate cancer is expected to steadily rise over the specified period, driven by factors such as an aging population, advancements in medical technology, and the increasing prevalence of prostate cancer. The CAGR provides valuable insight into the expected average annual growth rate of the market, indicating a positive trend and potential opportunities for growth and investment in this sector.
As per the World Health Organisation, there were around 9.6 million deaths due to cancer in 2018.
The statistic stating that there were around 9.6 million deaths due to cancer in 2018, as per the World Health Organization, highlights the significant global health burden posed by cancer. This statistic reflects the serious impact of cancer as a leading cause of death worldwide, emphasizing the urgent need for effective prevention strategies, early detection initiatives, and improved treatments to address this pervasive and devastating disease. The large number of deaths underscores the importance of prioritizing cancer research, healthcare resources, and public health efforts to reduce cancer mortality rates and improve outcomes for individuals affected by this complex and multifaceted health challenge.
Among women, breast cancer has the most incidences with 2.3 million new cases in 2020.
The statistic “Among women, breast cancer has the most incidences with 2.3 million new cases in 2020” indicates that breast cancer had the highest number of new diagnoses among all types of cancer in women for that year. The figure of 2.3 million new cases emphasizes the significant burden that breast cancer poses on women’s health globally. This statistic underscores the importance of continued research, awareness, and early detection efforts to address and combat this widespread and impactful disease that affects millions of women each year.
Gastrointestinal cancer treatment market is projected to achieve 5% CAGR up to 2026.
This statistic indicates that the gastrointestinal cancer treatment market is expected to experience a Compound Annual Growth Rate (CAGR) of 5% until the year 2026. This suggests a steady growth trajectory in the market for treatments related to gastrointestinal cancers over the specified period. This growth rate reflects the increasing demand for advanced treatment options, technological advancements, and potentially rising incidences of gastrointestinal cancers. Stakeholders in the healthcare industry can use this projection to anticipate market trends, make informed decisions on investments, and develop strategies to meet the needs of patients with gastrointestinal cancers.
Cervical cancer treatment market size is projected to cross USD 10.5 Billion by 2027.
The statistic “Cervical cancer treatment market size is projected to cross USD 10.5 Billion by 2027” indicates the estimated value of the market focused on products and services related to the treatment of cervical cancer. This projection suggests a growing economic opportunity within the healthcare industry for companies involved in developing, manufacturing, and providing treatments for cervical cancer. The projected increase in market size to over USD 10.5 Billion by 2027 signals significant investment, research, and demand for treatments specific to cervical cancer. This information is crucial for stakeholders, investors, and healthcare professionals to understand the potential market growth and opportunities in the field of cervical cancer treatment.
The anti-cancer drugs segment dominated the market with a share of almost 60% in 2019.
The statistic indicates that in 2019, the market for cancer drugs was largely dominated by the segment of anti-cancer drugs, which accounted for nearly 60% of the total market share. This suggests that anti-cancer drugs were the most popular and widely used category of drugs within the market, likely due to their effectiveness in treating various types of cancer. The high market share indicates that both healthcare providers and patients have a strong preference for anti-cancer drugs over other types of medications for cancer treatment. This dominance of the anti-cancer drugs segment highlights the significant impact and importance of these medications in the treatment and management of cancer.
There are more than 4000 new oncology trials initiated annually in the US.
The statistic “There are more than 4000 new oncology trials initiated annually in the US” indicates the considerable volume of clinical research in the field of oncology taking place in the United States each year. This statistic reflects the ongoing efforts to advance cancer treatment and care through the testing of new therapies, interventions, and diagnostic approaches. The large number of new trials highlights the significant investment and commitment from researchers, healthcare providers, pharmaceutical companies, and government agencies to improve outcomes and quality of life for cancer patients. The proliferation of oncology trials underscores the dynamic nature of cancer research and the continuous search for innovative solutions to combat this complex and challenging disease.
References
0. – https://www.www.statista.com
1. – https://www.www.prnewswire.com
2. – https://www.www.who.int
3. – https://www.www.marketsandmarkets.com
4. – https://www.www.acumenresearchandconsulting.com
5. – https://www.www.gminsights.com
6. – https://www.www.cancer.org
7. – https://www.www.alliedmarketresearch.com
8. – https://www.www.ncbi.nlm.nih.gov
9. – https://www.gco.iarc.fr
10. – https://www.www.grandviewresearch.com
11. – https://www.www.arizton.com
12. – https://www.www.fortunebusinessinsights.com
13. – https://www.www.wcrf.org
14. – https://www.www.globenewswire.com
